Neumora Therapeutics Inc.... (NMRA)
0.68
-0.00 (-0.26%)
At close: Apr 14, 2025, 12:50 PM
-0.26% (1D)
| Bid | 0.49 |
| Market Cap | 110.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -243.79M |
| EPS (ttm) | -1.53 |
| PE Ratio (ttm) | -0.44 |
| Forward PE | -1.26 |
| Analyst | Hold |
| Ask | 0.88 |
| Volume | 283,198 |
| Avg. Volume (20D) | 1,684,152 |
| Open | 0.69 |
| Previous Close | 0.68 |
| Day's Range | 0.67 - 0.70 |
| 52-Week Range | 0.62 - 17.19 |
| Beta | 2.90 |
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in pa...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 15, 2023
Employees 110
Stock Exchange NASDAQ
Ticker Symbol NMRA
Website https://www.neumoratx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for NMRA stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 634.86% from the latest price.
Stock Forecasts3 months ago
+14.29%
Neumora Therapeutics shares are trading higher. B ...
Unlock content with
Pro Subscription
3 months ago
-81.42%
Neumora Therapeutics shares are trading lower after the company announced its Phase 3 KOASTAL study did not demonstrate statistically significant improvement on its primary endpoint.
